Form 4: Travere Therapeutics CFO Reports Equity Transactions

Travere Therapeutics' CFO, Christopher R. Cline, reported the acquisition of common stock and stock options, alongside a tax-related 'sell to cover' transaction.

Summary

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (TVTX), reported changes in his beneficial ownership of company securities.
• On January 31, 2026, Cline acquired 28,130 shares of common stock through the settlement of restricted stock units (RSUs) at a price of $0 per share.
• Following this acquisition, his direct beneficial ownership of common stock increased to 120,213 shares.
• Also on January 31, 2026, Cline was granted 75,000 employee stock options with an exercise price of $33.095 per share, expiring on January 31, 2036.
• These options vest over time, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
• On February 3, 2026, Cline disposed of 7,242 shares of common stock at a price of $32.12 per share.
• This disposition was a non-discretionary 'sell to cover' transaction, mandated by the Issuer's equity incentive plans, to satisfy tax withholding obligations related to the vested restricted stock units.
• After the 'sell to cover' transaction, Cline's direct beneficial ownership of common stock stands at 112,971 shares, in addition to the 75,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the 'sell to cover' reduces direct holdings, it's a non-discretionary tax event. The significant grant of new stock options indicates continued executive alignment and long-term incentive, which is generally a positive signal.

Positives

• The grant of 75,000 employee stock options aligns the Chief Financial Officer's long-term incentives with shareholder value creation.
• The settlement of 28,130 restricted stock units indicates a component of executive compensation being realized, reflecting past performance or tenure.

Negatives

• The disposition of 7,242 shares, while non-discretionary and for tax purposes, represents a reduction in the CFO's direct common stock holdings.

Risks

• No specific risks were mentioned in this Form 4 filing beyond the inherent market risks associated with holding equity securities.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The 'sell to cover' transaction is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a 'sell to cover' transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, often related to executive compensation. The reported RSU settlement and option grant are standard components of executive pay packages in the biotechnology and pharmaceutical industry, aiming to align management interests with long-term shareholder value. The 'sell to cover' transaction is a common, non-discretionary event for tax purposes when equity awards vest.

Comparison to Industry Standards

• The structure of equity compensation, including restricted stock units and stock options with vesting schedules, is a common practice across the biotechnology and pharmaceutical sectors, comparable to compensation strategies at companies like Biogen Inc. or Gilead Sciences, Inc. These mechanisms are designed to incentivize long-term performance and retention.
• The 'sell to cover' mechanism for tax withholding is a standard industry practice for equity compensation, ensuring compliance with tax obligations upon the vesting or exercise of awards, similar to procedures observed at most publicly traded companies offering equity incentives.

Related Party Transactions

• The 'sell to cover' transaction is a mandated sale by the Issuer's election under its equity incentive plans to cover tax withholding obligations, representing a transaction with the company's designated brokerage firm on behalf of the Issuer.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the CFO's interests with long-term shareholder value. The 'sell to cover' is a routine event and does not signal a discretionary change in confidence.
• Employees: The compensation structure reflects standard equity incentive practices, which can influence employee retention and motivation.

Next Steps

• One-fourth of the granted stock options will vest and become exercisable on the first anniversary of the grant date (January 31, 2026).
• The remaining stock options will vest in 36 equal monthly installments thereafter.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, CFO, Equity Compensation, Sell to Cover, Beneficial Ownership